Cabaletta Bio (CABA) Cash & Equivalents (2018 - 2025)

Cabaletta Bio's Cash & Equivalents history runs 8 years deep, the most recent figure standing at $133.6 million for Q4 2025.

• On a quarterly basis, Cash & Equivalents fell 18.52% year-over-year to $133.6 million in Q4 2025; TTM through Dec 2025 was $133.6 million, a 18.52% decrease from a year earlier, with the FY2025 full-year figure at $133.6 million, down 18.52% from the prior year.
• Cash & Equivalents rose to $133.6 million in Q4 2025 per CABA's latest filing, from $60.2 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $223.8 million in Q1 2024 and bottomed at $47.2 million in Q2 2022.
• The 5-year median for Cash & Equivalents is $127.0 million (2021), against an average of $132.1 million.
• Across the five-year window, Cash & Equivalents soared 273.82% in 2023 and tumbled 67.1% in 2025, its largest moves.
• Year by year, Cash & Equivalents stood at $122.2 million in 2021, then plunged by 33.23% to $81.6 million in 2022, then jumped by 136.79% to $193.2 million in 2023, then fell by 15.15% to $164.0 million in 2024, then fell by 18.52% to $133.6 million in 2025.
• Per Business Quant, the three latest CABA Cash & Equivalents figures stand at $133.6 million (Q4 2025), $60.2 million (Q3 2025), and $194.7 million (Q2 2025).